The trial investigated the drug in two separate cohorts of patients: Cohort A, which included 170 patients with heavily pretreated metastatic triple negative breast cancer (mTNBC) regardless of PD - L1 expression, and Cohort B, which included 52 patients with PD - L1 -
positive tumors who received it as first - line therapy.
Not exact matches
The targeted radiotherapy shrank
tumors for 71 % of patients
who had already failed standard chemotherapy, but these results came from a small trial that started with 30 patients and then added another 20 after
positive data started rolling in.
Currently, many patients
who acquire resistance to EGFR - targeted therapy undergo a
tumor biopsy and are designated as either
positive or negative for specific secondary mutations.
For those
who test
positive twice, the next step will be imaging to find the
tumor.
«The result was an extensive inhibition of
tumor growth and prevention of metastasis to the lung in HER2 -
positive animal models of breast cancer,» notes Navasona Krishnan, Ph.D., a postdoctoral investigator in the Tonks lab
who performed many of the experiments and is lead author on the paper reporting the results.
«The good news is that we discovered that a subset of patients
who had both high
tumor mutation burden and high PDL - 1
positive status did experience a significant benefit from immunotherapy,» says Carbone.
On the other hand, someone
who has not smoked and presents with a
tumor that turns out to be HPV -
positive, «that person is expected to survive,» Gillison says.
Of the 22 patients whose
tumors successfully grafted, six died before data from the mice were available, but in 13 of the remaining 16 cases, there was a
positive correlation between mouse and human results.2 In a second study, performed in collaboration with Manuel Hidalgo of the Spanish National Cancer Research Center, the team found that 6 of 13 patients with advanced solid
tumors who were treated based on results from personalized PDX mice had partial
tumor remissions, even in cases where genetic sequencing of the
tumor showed no actionable mutations.3
In patients
who exhibited a
positive response to TIL therapy, the researchers were able to use ddPCR technology to detect a transient peak in HPV cfDNA, a sign of
tumor death.